JP2012532879A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532879A5
JP2012532879A5 JP2012519703A JP2012519703A JP2012532879A5 JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5 JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012519703 A JP2012519703 A JP 2012519703A JP 2012532879 A5 JP2012532879 A5 JP 2012532879A5
Authority
JP
Japan
Prior art keywords
cancer
itpp
effective amount
therapeutically effective
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012519703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532879A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041250 external-priority patent/WO2011005886A1/en
Publication of JP2012532879A publication Critical patent/JP2012532879A/ja
Publication of JP2012532879A5 publication Critical patent/JP2012532879A5/ja
Pending legal-status Critical Current

Links

JP2012519703A 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法 Pending JP2012532879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22358309P 2009-07-07 2009-07-07
US61/223,583 2009-07-07
PCT/US2010/041250 WO2011005886A1 (en) 2009-07-07 2010-07-07 Method of reducing multi-drug resistance using inositol tripyrophosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127462A Division JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Publications (2)

Publication Number Publication Date
JP2012532879A JP2012532879A (ja) 2012-12-20
JP2012532879A5 true JP2012532879A5 (enExample) 2013-08-29

Family

ID=43429524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012519703A Pending JP2012532879A (ja) 2009-07-07 2010-07-07 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127462A Pending JP2015166393A (ja) 2009-07-07 2015-06-25 イノシトールトリピロリン酸を使用して多剤耐性を低減する方法

Country Status (7)

Country Link
US (3) US20120003327A1 (enExample)
EP (1) EP2451459B1 (enExample)
JP (2) JP2012532879A (enExample)
CN (2) CN102573853A (enExample)
MX (1) MX2012000383A (enExample)
RU (1) RU2563127C2 (enExample)
WO (1) WO2011005886A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
WO2018038253A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小ナノ化薬剤およびその利用
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
US20200390723A1 (en) * 2017-12-22 2020-12-17 Lo.Li. Pharma International S.R.L. Treatment of fibrosis with inositol
CN112074276A (zh) * 2018-05-03 2020-12-11 诺姆奥克塞斯公司 一种肌醇基免疫疗法
TWI686210B (zh) 2018-06-01 2020-03-01 國立清華大學 用以誘導病變組織血管正常化的套組及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6632797B2 (en) * 1996-06-24 2003-10-14 Matti Siren Method of treating angiogenesis
JP3989997B2 (ja) * 1997-04-08 2007-10-10 ポーラ化成工業株式会社 放射線増感剤の製造方法
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP4116793B2 (ja) * 1999-09-13 2008-07-09 良尋 高井 新規ニトロイミダゾール誘導体及びこれを含む画像診断薬
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
JP5028405B2 (ja) * 2005-03-18 2012-09-19 ノームオクシス インコーポレイテッド ヘモグロビンのアロステリックエフェクターとしてのミオイノシトール１，６：２，３：４，５トリピロリン酸のカルシウム塩
WO2007081315A1 (en) * 2006-01-06 2007-07-19 Oxyplus, Inc. Use of inositol-tripyrophosphate in treating tumors and diseases

Similar Documents

Publication Publication Date Title
Yan et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction
Sarkar et al. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells
Babajani et al. Recent advances on drug-loaded mesenchymal stem cells with anti-neoplastic agents for targeted treatment of cancer
Fan et al. Carrier-free, pure nanodrug formed by the self-assembly of an anticancer drug for cancer immune therapy
Sharma et al. A marine sponge alkaloid derivative 4-chloro fascaplysin inhibits tumor growth and VEGF mediated angiogenesis by disrupting PI3K/Akt/mTOR signaling cascade
Wang et al. Specific cell targeting with APRPG conjugated PEG–PLGA nanoparticles for treating ovarian cancer
FI3834882T3 (fi) Syövän hoitaminen käyttämällä sähkömagneettisia kenttiä yhdistelmänä muiden hoito-ohjelmien kanssa
Zhong et al. Targeting proinflammatory molecules using multifunctional MnO nanoparticles to inhibit breast cancer recurrence and metastasis
JP2011524904A5 (enExample)
CN102125717A (zh) 携带放射性粒子胆道内引流管
KR102087565B1 (ko) 혈관형성 의태의 저해제로서의 아릴-퀴놀린 유도체의 신규한 용도
JP2017530184A5 (enExample)
Manatunga et al. Effective delivery of hydrophobic drugs to breast and liver cancer cells using a hybrid inorganic nanocarrier: a detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry
RU2015147696A (ru) Способы лечения злокачественной опухоли
JP2007519609A5 (enExample)
AU2014219129B2 (en) Caged platinum nanoclusters for anticancer chemotherapeutics
RU2012104022A (ru) Способ уменьшения мультилекарственной резистентности с использованием трипирофосфата инозита
JP6785487B2 (ja) 低分子化合物による癌と線維化の抑制と再生促進の効果
Nobahari et al. Curcumin-loaded iron oxide nanoparticles coated with sodium alginate and hydroxyapatite and their cytotoxic effects against the HT-29 and MCF-7 cancer cell lines
JP2016526021A5 (enExample)
CN106459011A (zh) 作为抗肿瘤化合物的σ‑2受体配体药物缀合物、其合成方法及其用途
JP2017509672A5 (enExample)
Peng et al. Traceable nanoparticles with mitochondria-targeting pyruvate-Cu induce cuproptosis for enhanced triple-negative breast cancer therapy in a mouse model
Shao et al. Strategies of porous network quinolone polymers: A comprehensive evaluation of their biological activity
Manatunga et al. Effective delivery of hydrophobic drugs to breast (MCF-7) and Liver (HepG2) cancer cells: a detailed investigation using cytotoxicity assays, fluorescence imaging and flow cytometry